Pacific Biosciences of California (NASDAQ:PACB – Get Rating) had its target price decreased by equities researchers at Piper Sandler from $13.00 to $6.00 in a research note issued to investors on Sunday, The Fly reports. Piper Sandler’s target price indicates a potential upside of 2.74% from the company’s current price. Several other brokerages have also […]
Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Rating) has earned an average recommendation of “Buy” from the eight research firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the […]
Wall Street analysts predict that Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Rating) will report $32.75 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have made estimates for Pacific Biosciences of California’s earnings, with the highest sales estimate coming in at $34.46 million and the lowest estimate […]
Clearwater Capital Advisors LLC boosted its holdings in shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Rating) by 15.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 10,394 shares of the biotechnology company’s stock after buying an […]
GAM Holding AG lessened its stake in Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Rating) by 23.6% in the fourth quarter, Holdings Channel reports. The institutional investor owned 22,659 shares of the biotechnology company’s stock after selling 7,011 shares during the quarter. GAM Holding AG’s holdings in Pacific Biosciences of California were worth $464,000 […]